Lucid Diagnostics director granted 123K shares
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 123,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lucid Diagnostics (LUCD) director John R. Palumbo report on this Form 4?
What forfeiture conditions apply to the new LUCD restricted stock grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.